Are you Dr. Nahid?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 38 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
1001 Potrero Ave
5k1
San Francisco, CA 94110Phone+1 415-206-8313Fax+1 415-695-1551
Summary
- Dr. Payam Nahid, MD is a pulmonologist in San Francisco, California. He is currently licensed to practice medicine in California. He is affiliated with Zuckerberg San Francisco General Hospital and Trauma Center and is an Associate Professor at UCSF School of Medicine.
Education & Training
- University of California (San Francisco)Fellowship, Pulmonary Disease and Critical Care Medicine, 2001 - 2004
- Scripps Clinic/Scripps Green HospitalResidency, Internal Medicine, 1998 - 2001
- University of California (Irvine)Internship, Internal Medicine, 1997 - 1998
- University of California, Irvine, School of MedicineClass of 1997
Certifications & Licensure
- CA State Medical License 1999 - 2026
- American Board of Internal Medicine Critical Care Medicine
- American Board of Internal Medicine Pulmonary Disease
Publications & Presentations
PubMed
- 208 citationsTreatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice GuidelinePayam Nahid, Sundari Mase, Giovanni Battista Migliori, Giovanni Sotgiu, Graham H. Bothamley
American Journal of Respiratory and Critical Care Medicine. 2019-11-15 - 189 citationsDrug-resistant tuberculosis: time for visionary political leadershipIbrahim Abubakar, Matteo Zignol, Dennis Falzon, Mario C. Raviglione, Lucica Ditiu
The Lancet. Infectious Diseases. 2013-06-01 - 198 citationsFour-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis.Susan E. Dorman, Payam Nahid, Ekaterina V. Kurbatova, Patrick P. J. Phillips, Kia E Bryant
The New England Journal of Medicine. 2021-05-06
Press Mentions
- UCSF Joins $200 Million Global Tuberculosis ConsortiumAugust 2nd, 2022
- Study: Four-Month Regimen of Anti-TB Drugs Works Just as Well as Standard RegimenMay 24th, 2021
- New TB Drug Regimen Controls Resistant Disease in 9 of 10 Cases: StudyMarch 4th, 2020
- Join now to see all
Grant Support
- Interplay Of Strain And Ethnicity In The Immune Response To M. TuberculosisNational Heart, Lung, And Blood Institute2007–2011